TWST, the stock of Twist Bioscience Corporation, a South San Francisco-based synthetic biology company that manufactures synthetic DNA and next-generation sequencing tools on a proprietary silicon platform, moved higher in midday trading on Wednesday. Shares advanced about +4.12% to approximately $137.57, up from a prior session close of $132.13. The gain extended a multi-day recovery after a sharp short-seller-driven selloff, supported by renewed enthusiasm for AI-enabled biotech and positioning ahead of the company's upcoming earnings release.
The most immediate catalyst behind today's move is a continuing bounce from last week's sharp decline. On November 5, shares of TWST fell roughly 10% to 15% after a report from The Bear Cave (published by Hunterbrook Media) argued that market optimism had outpaced the economics of the company's core DNA-synthesis business. The report questioned whether the company's AI-related collaborations represented a proprietary partnership or a more routine commercial relationship.
Since then, buyers have stepped in around the $120 level, treating it as near-term support. The stock rebounded sharply on Monday, pulled back modestly on Tuesday, and resumed its advance on Wednesday as short-term momentum and short covering supported the recovery.
The rebound is also riding a broader wave of enthusiasm for AI-adjacent life-science tools. TWST has become a focal point of the "generative AI in biotech" narrative, with investors connecting its synthetic DNA platform to AI-enabled drug-discovery workflows. Strength across peers in the genomics and sequencing-tools space — including names such as TXG and TEM — has reinforced the sector-wide bid for "picks-and-shovels" suppliers to drug developers.
Adding to the move is positioning ahead of the company's next quarterly results, scheduled for November 12. With the stock having whipsawed violently over the past week, traders are re-establishing exposure into the print, betting that solid revenue growth and gross-margin commentary could help validate a valuation that remains elevated relative to peers.
The advance occurred within a supportive backdrop for high-beta biotech names, aided by easing Treasury yields and an uptick in risk appetite. Trading volume was active but roughly in line with the stock's historically elevated turnover. The move marks a further step in a high-volatility stretch: after surging roughly ninefold from its 52-week low near $23 to a high near $220 earlier this year, shares have oscillated sharply as bulls and bears debate whether the AI premium is justified. Technically, the $120 zone has emerged as the key support to watch, while the low-to-mid $150s represent the next notable resistance band.
The near-term focus is squarely on the November 12 earnings report. Investors will watch revenue growth, gross margins, and any commentary on AI-related partnerships and the newly launched MRD diagnostic product. The company remains unprofitable on a trailing-twelve-month basis, so the stock's valuation carries much of the investment thesis. Risks include further scrutiny of the AI narrative, potential insider selling, elevated volatility, and the possibility that a decisive close below $120 reignites selling pressure. Conversely, strong results and continued sector momentum could keep the recovery intact.
Tickeron offers hundreds of AI-powered trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in the curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, allowing traders to explore automated approaches tailored to today's market environment. Visit Trending AI Robots to review the current top performers and see how AI-driven strategies are navigating this market.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Following a +12.21% 3-day Advance, the price is estimated to grow further. Considering data from situations where TWST advanced for three days, in 235 of 291 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
The 10-day RSI Indicator for TWST moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 45 similar instances where the indicator moved out of overbought territory. In 35 of the 45 cases, the stock moved lower in the following days. This puts the odds of a move lower at 78%.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TWST as a result. In 70 of 76 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for TWST turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 36 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.
TWST moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for TWST crossed bearishly below the 50-day moving average on October 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TWST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
TWST broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for TWST entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.967) is normal, around the industry mean (3.498). P/E Ratio (-54.166) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (20.243) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. TWST’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 85 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 86 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TWST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of proprietary semiconductor-based synthetic DNA manufacturing process
Industry Biotechnology